MedPath
Found 8 clinical trials|View Analysis
Sort by:

CHAAMP (Charlotte African American MGUS Project) Internal Pilot Study

Not yet recruiting
Conditions
Multiple Myeloma
Multiple Myeloma Progression
Monoclonal Gammopathy of Undetermined Significance (MGUS)
Smoldering Multiple Myeloma (SMM)
Plasma Cell Disorders
First Posted Date
2024-10-16
Last Posted Date
2024-10-16
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
1665
Registration Number
NCT06644625
Locations
🇺🇸

Atrium Health Levine Cancer, Charlotte, North Carolina, United States

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

Phase 2
Recruiting
Conditions
Monoclonal Gammopathy of Undetermined Significance (MGUS)
Smoldering Multiple Myeloma (SMM)
Interventions
First Posted Date
2023-11-20
Last Posted Date
2025-01-09
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
104
Registration Number
NCT06140524
Locations
🇺🇸

Johns Hopkins Hospital, Baltimore, Maryland, United States

🇪🇸

Hospital Clinico Universitario Virgen De La Arrixaca, El Palmar, Murcia, Spain

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 5 locations

A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM)

Not Applicable
Recruiting
Conditions
Multiple Myeloma, Smoldering
Interventions
Dietary Supplement: Probiotic
Dietary Supplement: Curcumin
Dietary Supplement: Omega-3
Other: Whole food, plant-based diet (WFPBD)
First Posted Date
2023-09-28
Last Posted Date
2024-08-22
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
100
Registration Number
NCT06055894
Locations
🇺🇸

Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States

and more 4 locations

A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma

Phase 2
Recruiting
Conditions
Smoldering Multiple Myeloma (SMM)
Interventions
First Posted Date
2023-07-21
Last Posted Date
2024-12-19
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
40
Registration Number
NCT05955508
Locations
🇪🇸

Hospital Universitario Ramon y Cajal, Madrid, Spain

🇪🇸

Clinica Universidad de Navarra - Madrid, Madrid, Spain

🇪🇸

University Hospital Doctor Peset, Valencia, Spain

and more 14 locations

A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)

Not Applicable
Recruiting
Conditions
Multiple Myeloma
Monoclonal Gammopathy of Undetermined Significance
Interventions
Other: Placebo supplements
Other: Whole Foods Plant-based Diet
Dietary Supplement: Algae omega 3
First Posted Date
2022-12-07
Last Posted Date
2025-01-09
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
150
Registration Number
NCT05640843
Locations
🇺🇸

Emory University (Data Collection Only), Atlanta, Georgia, United States

🇺🇸

Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States

and more 5 locations

A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)

Not Applicable
Active, not recruiting
Conditions
Smoldering Multiple Myeloma
Monoclonal Gammopathy of Undetermined Significance
Interventions
Other: Plant based meals
First Posted Date
2021-06-09
Last Posted Date
2024-03-29
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
23
Registration Number
NCT04920084
Locations
🇺🇸

Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States

and more 4 locations

Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer

Phase 2
Recruiting
Conditions
Prostate Cancer
Multiple Myeloma
Monoclonal Gammopathy of Undetermined Significance
Smoldering Multiple Myeloma (SMM)
Interventions
First Posted Date
2021-02-01
Last Posted Date
2024-07-12
Lead Sponsor
University of Rochester
Target Recruit Count
40
Registration Number
NCT04731844
Locations
🇺🇸

University of Rochester, Rochester, New York, United States

Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer

Phase 1
Conditions
Smoldering Multiple Myeloma (sMM)
Acute Myelogenous Leukemia (AML)
Multiple Myeloma (MM)
Myelodysplastic Syndrome (MDS)
Interventions
Drug: Sargramostim
Drug: BB-MPI-03
Drug: Montanide
First Posted Date
2014-09-15
Last Posted Date
2016-04-19
Lead Sponsor
Benovus Bio, Inc.
Target Recruit Count
4
Registration Number
NCT02240537
Locations
🇺🇸

University of Chicago, Chicago, Illinois, United States

🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

🇺🇸

Virginia Cancer Specialists, Fairfax, Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath